Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: Improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties

Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2002, Pages 973-983

  Nair, Anil C ^b,c   Jayatilleke, Philippa ^b,d   Wang, Xia ^b,e   Miertus, Stanislav ^f   Welsh, William J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^c Aventis Pharmaceuticals   (United States)

^d TRIPOS INC   (United States)

^e ASTRAZENECA   (United Kingdom)

^f UNIDO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TETRAHYDROPYRIMIDINE 2 ONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CALCULATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPLEX FORMATION; DRUG RECEPTOR BINDING; ELECTRIC FIELD; ENERGY; HUMAN IMMUNODEFICIENCY VIRUS 1; LINEAR REGRESSION ANALYSIS; MOLECULAR MODEL; PROTEINASE INHIBITION; SOLVATION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

HIV PROTEASE; LIGANDS; PROTEASE INHIBITORS; PROTEIN BINDING; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 0037075124     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010417v     Document Type: Article

References (33)

1. Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne)
2. Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases
3. A deletion mutation in the 5′ part of the pol gene of moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins
4. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity
5. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation
6. Molecular recognition of protein-ligand complexes: Application to drug design
7. Resistance to human immunodeficiency virus type 1 protease inhibitors
8. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
9. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors
10. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site
11. Comparative binding energy analysis of HIV-1 protease inhibitors: Incorporation of solvent effects and validation as a powerful tool in receptor-based drug design
12. CADD of new pseudo-peptide inhibitors of HIV-1 aspartic protease
13. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: Analysis and tuning of the subsite specificity
14. Design of new inhibitors of HIV-1 aspartic protease
15. A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues
16. Computational studies on HIV-1 protease inhibitors: Influence of calculated inhibitor - Enzyme binding affinities on the statistical quality of 3D-QSAR comparative molecular field analysis (CoMFA) models
17. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: Application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease
18. Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations
19. Structure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors
20. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: A molecular modeling study
21. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: Application of comparative molecular field analysis
22. Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors
23. Iterative partial equalization of orbital electronegativities: A rapid access to atomic charges
24. Bootstrapping, crossvalidation and partial least squares
25. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidine-2-one HIV protease inhibitors
26. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors